A total of 465 patients with ACS-induced new-onset HF during the index admission were identified as eligible subjects, after excluding subjects with AKI, CKD with CrCl < 25 ml/min/1.73 m2, and known HF with reduced EF and those who dispensed SGLT2 inhibitors for less than the follow-up period post-discharge. Here, SLC5A2 is linked to chronic kidney disease.